Oncotarget

Research Papers:

Next-generation sequencing reveals microRNA markers of adrenocortical tumors malignancy

Łukasz Koperski _, Marta Kotlarek, Michał Świerniak, Monika Kolanowska, Anna Kubiak, Barbara Górnicka, Krystian Jażdżewski and Anna Wójcicka

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:49191-49200. https://doi.org/10.18632/oncotarget.16788

Metrics: PDF 1120 views  |   HTML 1902 views  |   ?  


Abstract

Łukasz Koperski1, Marta Kotlarek2, Michał Świerniak2,3, Monika Kolanowska2,3, Anna Kubiak2,3, Barbara Górnicka1, Krystian Jażdżewski2,3 and Anna Wójcicka2,3

1Department of Pathology, Medical University of Warsaw, Warsaw, Poland

2Laboratory of Human Cancer Genetics, Center of New Technologies, CENT, University of Warsaw, Warsaw, Poland

3Genomic Medicine, Medical University of Warsaw, Warsaw, Poland

Correspondence to:

Anna Wójcicka, email: anna.wojcicka@uw.edu.pl

Keywords: microRNA, adrenocortical carcinoma, cancer diagnostics, next-generation sequencing, NGS

Abbreviations: AA, adrenocortical adenoma; ACC, adrenocortical carcinoma; NA, normal adrenal cortex; NGS, next-generation sequencing

Received: May 03, 2016    Accepted: March 16, 2017    Published: April 03, 2017

ABSTRACT

Background: Adrenocortical carcinoma is a rare finding among common adrenocortical tumors, but it is highly aggressive and requires early detection and treatment. Still, the differential diagnosis between benign and malignant lesions is difficult even for experienced pathologists and there is a significant need for novel diagnostic methods. In this study we aimed to reveal a complete set of microRNAs expressed in the adrenal gland and to identify easily detectable, stable and objective biomarkers of adrenocortical malignancy.

Methods: We employed next-generation sequencing to analyze microRNA profiles in a unique set of 51 samples, assigned to either a learning dataset including 7 adrenocortical carcinomas (ACCs), 8 adrenocortical adenomas (AAs) and 8 control samples (NAs), or a validation dataset including 8 ACCs, 10 AAs and 10 NAs. The results were validated in real-time Q-PCR.

Results: We detected 411 miRNAs expressed in 1763 length isoforms in the examined samples. Fifteen miRNAs differentiate between malignant (ACC) and non-malignant (AA + NA) tissue in the test set of independent samples. Expression levels of 6 microRNAs, miR-503-5p, miR-483-3p, miR-450a-5p, miR-210, miR-483-5p, miR-421, predict sample status (malignancy/non-malignancy) with at least 95% accuracy in both datasets. The best single-gene malignancy marker, miR-483-3p, has been validated by real-time RT PCR.

Conclusions: As a result of the study we propose clinically valid and easily detectable biomarkers of adrenocortical malignancy that may significantly facilitate morphological examination. Since microRNAs can be detected in blood, the study brings tools for development of non-invasive diagnostics of adrenocortical carcinomas.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16788